What's New in AML Post ASCO 2019: BCL-2 Inhibitors

8 drugs have been approved in the past two years with additional drugs under investigation. Visit this channel to keep up on what's New in AML.

 

What's New in AML Post ASCO 2019: BCL-2 Inhibitors
18:46

What's New in AML Post ASCO 2019: BCL-2 Inhibitors

New Targets for Acute Myeloid Leukemia: FLT3, IDH1 &IDH2, CD33, BCL-2, Hedgehog Signaling Pathway, and New Directions in E-selectin and Immunotherapy

FEATURING Eunice Wang
  • 497 views
  • August 9, 2019
  • 3
23:45

What's New in AML Post ASCO 2019: BCL-2 Inhibitors

BCL-2 Inhibitor Based Therapy in AML

FEATURING Marina Konopleva
  • 675 views
  • August 20, 2019
  • 3
15:41

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Targeted Therapy Drugs for AML - CPX-351, FLT3, IDH Inhibitors, BCL-2, & Hedgehog Pathway Inhibitor

FEATURING Tara Lin
  • 245 views
  • August 19, 2019
  • 1
27:00

Indy Hematology Review

Acute Myeloid Leukemia - Overview of Available Novel Agents with Unique Mechanisms of Action

FEATURING Martin Tallman
  • 1,770 views
  • June 7, 2019
  • 13